Search
Tyneco: Subsidiary CKBA Cream Receives Approval for Rosacea Drug Clinical Trial Application
4 week ago /
Read about 0 minute
Author：小编
Tyneco has announced that its subsidiary Bocyuan has received an acceptance notice from the National Medical Products Administration (NMPA), granting approval for a seamless adaptive Phase II/III clinical trial of CKBA Cream for the treatment of rosacea. CKBA Cream, a small molecule drug with independent intellectual property rights, boasts a novel structure and excellent safety profile. This development is not expected to have a significant impact on the company's short-term financial condition or operational performance.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
